Founded in 2003 and privately held, Portola is dedicated to the discovery
and development of novel therapeutics for the treatment and prevention of
cardiovascular diseases. Portola has one of the most experienced discovery
and development teams in the areas of vascular thrombosis and inflammation.
The company believes that its integrated discovery and development approach
applied to its comprehensive understanding of platelet physiology and vascular
thrombosis will allow it to develop new therapeutics where current
antithrombotic therapies are inadequate.
